Ciprofloxacin's Role in Disrupting Biofilms and Antibiotic Resistance in Uropathogenic Escherichia coli from Anbar Provinces | ||
| Egyptian Journal of Veterinary Sciences | ||
| Article 22, Volume 56, Issue 9, September 2025, Pages 2207-2215 PDF (716.83 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejvs.2024.288261.2069 | ||
| Authors | ||
| Hadeel Ahmed Knoush* ; Abdul Salam Abdul Sattar; Ali Mahdi Oudah; Khalid Jamal Abd-Alhadi; Khattab Ahmad Reehan; Hanan Aamer Hikmat | ||
| Department of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al-Maarif, Al-Anbar, 31001, Iraq. | ||
| Abstract | ||
| Escherichia coli (E. coli) is responsible for 70%-95% of urinary tract infections (UTIs), with biofilm formation significantly contributing to antibiotic resistance. This study investigates the relationship between biofilm formation and antibiotic resistance in uropathogenic E. coli, and assesses the effect of Ciprofloxacin (CIP) on biofilm development. E. coli strains were isolated from UTI patients and their biofilm-forming abilities were evaluated using Tube and Microtiter plate assays. The minimum inhibitory concentration (sub-MIC) of CIP was determined through resazurin assays and growth curve analysis. The impact of CIP on biofilm formation was assessed by comparing biofilm production in treated versus untreated isolates, with statistical significance determined using the t-test (p < 0.05). Out of 35 samples, 30 E. coli isolates were identified, with 98% exhibiting biofilm production of varying intensities (strong, moderate, and weak). The sub-MIC of CIP was found to be 0.1 mg/ml, which reduced biofilm formation by 75%, lowering the mean biofilm production from 0.06 to 0.02, with statistically significant results (p < 0.05). The findings suggest a notable link between biofilm formation, antibiotic resistance, and E. coli pathogenicity. Sub-MIC CIP effectively inhibits biofilm formation without adversely affecting bacterial growth, indicating its potential as a therapeutic option for managing biofilm-associated bacterial infections. | ||
| Keywords | ||
| urinary tract infections; Uropathogenic E. coli; MDR; Biofilm; Ciprofloxacin; Antibiotic Resistance | ||
|
Statistics Article View: 272 PDF Download: 188 |
||
